Bio/Pharma News

Hospira acquires assets from Orchid Chemicals & Pharmaceuticals for $218 million.

The FDA approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma.

FDA grants breakthrough therapy designation to Novartis chimeric antigen receptor therapy.

Genentech's $1.7 billion acquisition of Seargon Pharmaceutical includes portfolio of investigational next-generation oral selective estrogen receptor degraders.

Sandoz will supply antibiotic to developing countries as part of the United Nations' Every Newborn Action Plan.

GSK and Save the Children announce criteria for awards that recognize innovation in healthcare for the world&s poorest children.

Aesica Pharmaceuticals S.r.I. collaborates with QAD to meet China&s Food and Drug Administration's shortened serialization deadline.

Novartis' 13th Annual Malaria Expert Panel focused on access to quality anti-malarials across Africa.

Abbott will acquire a controlling interest in the Russian pharmaceutical manufacturer Veropharm.

The new mAb manufacturing facility in Switzerland will supply material for clinical development.

Merck acquires Idenix Pharmaceuticals for $3.85 billion.

Cellectis enters an agreement with CELLforCURE for cGMP clinical manufacturing of allogeneic T-cells.

Bayer extends its CEO contract with Marijn Dekkers until 2016.

Genia's DNA-sequencing platform will strengthen Roche's pipeline.

Alexion initiates a voluntary nationwide recall of certain lots of soliris (eculizumab) concentrated solution for intravenous infusion because of visible particulate matter in a single lot.

AMRI adds commercial-scale sterile injectable manufacturing capabilities with acquisition of Oso Biopharmaceuticals.

Aastrom acquires Sanofi's CTRM business unit for $6.5 million.

PharmaCell has finalized its purchase of the cell therapy production facility from TiGenix.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.

Bristol-Myers Squibb announced collaborations with CytomX on probodies and with Incyte in an immunotherapy clinical trial.

Actavis develops a solid dosage manufacturing and packing facility at its Manati site in Puerto Rico.

GSK reports 5-year vaccine price freeze for countries graduating from GAVI Alliance.

GE Healthcare launches the Xuri IL-2 for the activation and expansion of T-lymphocytes.

Merck KGaA fill-finish expansion in Italy will be completed in 2017.

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

Pfizer will submit a NDA with FDA for palbociclib, a treatment for locally advanced or metastatic breast cancer.

BMS and AbbVie receive FDA breakthrough therapy designation for elotuzumab, an investigational humanized monoclonal antibody for multiple myeloma.

Novartis settles its litigation with the US subsidiary of Sun Pharma regarding Gleevec.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.